In vivo anti-tumor mechanism(s) of sorafenib were additionally investigated by analyzing Akt and ERK1/2 phosphorylation in sorafenib-treated tumor cells and tumor vasculature (Figure 7). The gene discussed is AKT1; the disease is neoplasm.